KR960705578A - 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease) - Google Patents

경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease)

Info

Publication number
KR960705578A
KR960705578A KR1019960702207A KR19960702207A KR960705578A KR 960705578 A KR960705578 A KR 960705578A KR 1019960702207 A KR1019960702207 A KR 1019960702207A KR 19960702207 A KR19960702207 A KR 19960702207A KR 960705578 A KR960705578 A KR 960705578A
Authority
KR
South Korea
Prior art keywords
peptide
thymosin
biologically active
serum
per square
Prior art date
Application number
KR1019960702207A
Other languages
English (en)
Inventor
에프. 샤슈미트 브루스
디. 박스터 죤
엘. 호위츠 데이비드
Original Assignee
도널드 알.셀러즈
시클론 파마수티컬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도널드 알.셀러즈, 시클론 파마수티컬스 filed Critical 도널드 알.셀러즈
Priority claimed from PCT/US1993/010343 external-priority patent/WO1995011688A1/en
Publication of KR960705578A publication Critical patent/KR960705578A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

티모신 α-1, 또는 티모신 α-1의 생물학적 활성단편 또는 유사체는 경증 B형 간염 감염의 치료를 위해 투여된다.

Description

경증 질환을 가진B형 간염 보균자의 치료방법(METHOD FOR TREATING HEPATITIS B CARRIERS WITH MINIMAL DISEASE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 약학적으로 허용되는 비히클내에 티모신α-1, 티모신 α-1의 생물학적 활성 단편, 및 티모신 α-1의 생물학적 활성 유사체로 구성된 군으로부터 선택되는 적어도 하나의 펩티드의 치료적으로 효과적인 양을 환자에게 투여하는 것으로 이루어지는 환자의 경증 B형 간염 감염의 치료방법.
  2. 제1항에 있어서, 상기 펩티드는 티모신 α-1인 것을 특징으로 하는 방법.
  3. 제1항에 있어서, 상기 펩티드는 티모신 α-1의 생물학적 활성단편인 것을 특징으로 하는 방법.
  4. 제1항에 있어서, 상기 펩티드는 티모신 α-1의 생물학적 활성유사체인 것을 특징으로 하는 방법.
  5. 제1항에 있어서, 상기 투여는 피하경로에 의하는 것을 특징으로 하는 방법.
  6. 제1항에 있어서, 체내 혈청의 평방미터당 약 400 내지 약 3200㎍의 상기 펩티드가 투여되는 것을 특징으로 하는 방법.
  7. 제1항에 있어서, 체내 혈청의 평방미터당 약 600 내지 약 3000㎍의 상기 펩티드가 투여되는 것을 특징으로 하는 방법.
  8. 제1항에 있어서, 체내 혈청의 평방미터당 약 600 내지 약 1500㎍의 상기 펩티드가 투여되는 것을 특징으로 하는 방법.
  9. 제1항에 있어서, 체내 혈청의 평방미터당 약 900 내지 약 1200㎍의 상기 펩티드가 투여되는 것을 특징으로 하는 방법.
  10. 제6항 내지 제9항 중 어느 한 항에 있어서, 체내 상기 펩티드는 주2회 투여되는 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702207A 1992-02-06 1993-10-28 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease) KR960705578A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/833,468 US5308833A (en) 1992-02-06 1992-02-06 Method for treating hepatitis B carriers with minimal disease
PCT/US1993/010343 WO1995011688A1 (en) 1992-02-06 1993-10-28 Method for treating hepatitis b carriers with minimal disease
CN93120725A CN1054775C (zh) 1992-02-06 1993-10-29 胸腺素α-1、其活性片段或类似物在制备治疗轻微疾病性乙型肝炎药物中的应用

Publications (1)

Publication Number Publication Date
KR960705578A true KR960705578A (ko) 1996-11-08

Family

ID=36928436

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702207A KR960705578A (ko) 1992-02-06 1993-10-28 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease)

Country Status (4)

Country Link
US (1) US5308833A (ko)
KR (1) KR960705578A (ko)
CN (1) CN1054775C (ko)
AU (1) AU703480B2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
US5750501A (en) * 1993-11-05 1998-05-12 Alpha 1 Biomedicals, Inc. Method and composition for treatment of patients having decompensated liver disease
US5939423A (en) * 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6288033B1 (en) 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
CN100346757C (zh) * 2002-06-07 2007-11-07 余钢纲 一种妇女用卫生巾和卫生护垫
CN100372870C (zh) * 2003-03-21 2008-03-05 中国人民解放军军事医学科学院毒物药物研究所 胸腺素α1的聚乙二醇化衍生物
CN101448519B (zh) * 2006-05-19 2012-02-15 希格马托制药工业公司 胸腺素α1在免疫疾病治疗中的用途
US20100190722A1 (en) * 2007-09-11 2010-07-29 Dorian Bevec Substance p and thyrotropin releasing hormone for therapeutic applications
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4264571A (en) * 1979-01-22 1981-04-28 George Washington University Radioimmunoassay of thymosin α1
US4339427A (en) * 1980-04-14 1982-07-13 Hoffmann-La Roche Inc. Radioimmunoassay of thymosinα
US4855407A (en) * 1985-04-11 1989-08-08 Alpha-1 Biomedicals, Inc. Solid phase process for synthesizing peptides

Also Published As

Publication number Publication date
CN1102124A (zh) 1995-05-03
AU703480B2 (en) 1999-03-25
CN1054775C (zh) 2000-07-26
AU5454294A (en) 1995-05-22
US5308833A (en) 1994-05-03

Similar Documents

Publication Publication Date Title
EP1317929A3 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
BG104370A (en) Composition improving the penetration into the skin
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
ATE120091T1 (de) Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz.
KR960705578A (ko) 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease)
CA2122058A1 (en) Tgf-beta to improve neural outcome
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
RU95113824A (ru) Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции
KR910700069A (ko) Gm-csf를 사용한 백혈구 기능장애의 치료
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
KR960700741A (ko) 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment)
NZ284914A (en) use of anti-arthritogenic peptide antibodies, nonadsorbable antibiotic or benign bacteria to treat rheumatoid arthritis by enteral administration
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
KR900701322A (ko) 포도필린과 재조합 DNA인간 α인터페론의 배합물로 생식기 우췌를 치료하는 방법
Miller et al. Effect of penicillin dosage schedule on treatment of experimental typhoid infections in mice
KR890011572A (ko) 정신 기능을 증진시키는 방법
NO961685L (no) Fremgangsmåte for behandling av hepatitt-B-bærere med minimal sykdom
ATE152911T1 (de) Verwendung von bilobalid und deren derivate zur behandlung von infektionen bei menschen und für eine solche anwendung geeignete pharmazeutische zusammensetzung
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
MY109685A (en) Method for treating hepatitis b carriers with minimal disease

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid